These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 18025879)

  • 1. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
    Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
    AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
    Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
    HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
    Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
    Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
    Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
    Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
    Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
    J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.
    Chen M; Ssali F; Mulungi M; Awio P; Yoshimine H; Kuroki R; Furumoto A; Tanimura S; Kityo C; Nagatake T; Mugyenyi P; Oishi K
    Vaccine; 2008 Sep; 26(38):4962-8. PubMed ID: 18639599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.
    Rabian C; Tschöpe I; Lesprit P; Katlama C; Molina JM; Meynard JL; Delfraissy JF; Chêne G; Lévy Y;
    Clin Infect Dis; 2010 Apr; 50(8):1174-83. PubMed ID: 20210645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults.
    Peñaranda M; Payeras A; Cambra A; Mila J; Riera M;
    AIDS; 2010 May; 24(8):1226-8. PubMed ID: 20299956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine.
    Balmer P; Borrow R; Arkwright PD
    Vaccine; 2007 Aug; 25(34):6321-5. PubMed ID: 17629373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
    Falcó V; Jordano Q; Cruz MJ; Len O; Ribera E; Campins M; Crespo M; Ocaña I; Rodrigo MJ; Pahissa A
    Vaccine; 2006 Mar; 24(14):2567-74. PubMed ID: 16423429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
    Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
    J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
    Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
    Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children.
    Spoulou VI; Tsoumas DL; Papaevangelou VG; Mostrou GI; Theodoridou MC
    Vaccine; 2005 Nov; 23(46-47):5289-93. PubMed ID: 16054732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity.
    Uddin S; Borrow R; Haeney MR; Moran A; Warrington R; Balmer P; Arkwright PD
    Vaccine; 2006 Jul; 24(27-28):5637-44. PubMed ID: 16730399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
    Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP
    Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147).
    Slayter KL; Singer J; Lee TC; Kayhty H; Schlech WF
    Int J STD AIDS; 2013 Mar; 24(3):227-31. PubMed ID: 23535358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
    Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.